RxDoctor Payments Data

Chidambaram Rammohan, MD

Interventional Cardiology · Mountain View, CANPI 1477503308

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $163,739 of the $232,119 with a category attached, or 70.5%. Medtronic accounts for 91.0% of it on its own, with 21 other manufacturers making up the rest. Among interventional cardiology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$232,119in general payments, 2019–2025

Across 478 payments — averaging $485.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$211K
  • Abbott$15K
  • Edwards Lifesciences$2K
  • Boston Scientific$2K
  • Medical Device Business Services, Inc.$528
  • Shockwave Medical, Inc$377
  • plus $2K from 16 others
$357,255in research payments, 2019–2025

Across 125 payments — averaging $2858.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abbott$248K
  • Boston Scientific$109K

What the payments were for

  • Consulting fees$22,77310%
  • Speaking & faculty fees$163,73971%
  • Travel & lodging$33,37914%
  • Food & beverage$12,2125%
  • Education$160%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$232,119 in reported general payments places this provider in the 95th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$570,561
Medicare patients
1,254
Services billed
3,016

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban221$289,298
EntrestoSacubitril/Valsartan29$40,195
JardianceEmpagliflozin22$36,775
Repatha SureclickEvolocumab15$23,523
XareltoRivaroxaban13$12,726
Eplerenone16$3,687
Metoprolol Succinate221$3,614
Rosuvastatin Calcium204$2,399
Atorvastatin Calcium209$1,908
Valsartan42$1,656
Losartan Potassium91$1,589
ClopidogrelClopidogrel Bisulfate98$1,435
Ezetimibe48$1,164
Spironolactone91$1,080
Amlodipine Besylate137$1,021

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Mountain View

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →